Directorate change – Replacement
![]()
This announcement replaces the previous announcement at 7.12am this morning (RNS number 7748D) and includes, in the appendix, additional information disclosures required under AIM Rule 17. All other details remain unchanged. The full corrected version is set out below.
Uniphar plc
Directorate Changes
Dublin, London | 19 November 2026: Uniphar plc (the "Company" or "Uniphar"), an international diversified healthcare services business, is pleased to announce that the Board has approved the appointment of Roger Gillespie to its Board as an independent non-executive Director, with effect from 25 January 2027.
A Chartered Accountant, Roger has extensive experience in professional advisory services and board-level governance and leadership. In a career with KPMG stretching over four decades, Roger worked closely with some of Ireland’s largest publicly listed and private companies, in the role of Audit Partner and Deal Advisory Partner, serving clients in the healthcare, industrial, retail and agri food sectors.
Since retiring from KPMG in 2024, Roger has provided consultancy services and holds a number of non-executive board roles, including in the healthcare sector. Roger brings a detailed understanding of financial reporting, corporate governance, equity capital and debt markets and mergers and acquisitions.
Other Board Changes
Further to previous statements, the Board also announces that Maurice Pratt stepped down as Chair of the Company, and Paul Hogan took over the role of Chair, on 18 November 2026. Maurice will remain on the Board as a Director until 6 May 2027. Sue Webb also assumed the role of Senior Independent Director, replacing Paul Hogan, on 18 November 2026.
Ger Rabbette, Chief Executive Officer of Uniphar, commented:
"Maurice has served on the Uniphar Board for over 20 years, including as Chair for 17 years. In that time, Maurice has made an unparalleled contribution to Uniphar, guiding the company in the worst of times and the best of times. He saw Uniphar through the difficulties following the financial crisis of 2008, the acquisition of CMR, the recovery of the business and the expansion beyond Ireland into Europe, the US and beyond and, of course, to flotation in 2019.
Clear-headed and strategic, he always worked closely with his Board to provide the executive team with an ideal combination of challenge, sage advice and support.
An accomplished business leader, ambitious for the company and open to the ideas of others, Maurice has been more than instrumental in creating the environment which allows the Board and the business to believe that our greatest aspirations can be achieved. Both as a colleague and a friend, he will be sorely missed."
--- ENDS ---
Appendix
Additional Information:
Roger William Gillespe (Irish citizen, aged 66 years) holds 86,957 ordinary shares, and no options in the Company.
|
Current Directorships |
|
Robert J. Goff & Co. Public Limited Company |
|
Mawenzi Unlimited Company |
|
Mile Group Unlimited |
|
Glyde Group Unlimited |
|
Huntstown Holdings Unlimited |
|
Leonard GP Limited |
|
Orlagh GP Limited |
|
Rab Co-Invest Limited |
|
Previous Partnerships |
|
KPMG |
The Company confirms that there is no other information that is required to be disclosed under Schedule 2(g) of the AIM Rules for Companies.
Contact details
|
Uniphar Group
|
Tel: +353 (0) 1 428 7777 |
|
Allan Smylie, Head of Strategy and IR | |
|
| |
|
Davy (Joint Corporate Broker, Nominated Advisor and Euronext Growth Listing Sponsor)
|
Tel: +353 (0) 1 679 6363 |
|
Daragh O’Reilly Niall Gilchrist Ivan Murphy |
|
|
|
|
|
RBC Capital Markets (Joint Corporate Broker)
|
Tel: +44 (0) 20 7653 4000 |
|
Jamil Miah Daniel Saveski |
|
|
|
|
|
Stifel Nicolaus Europe Limited (Joint Corporate Broker)
|
Tel: +44 (0) 20 7710 7600 |
|
Matt Blawat Ben Maddison Francis North |
|
|
|
|
|
Q4 PR
|
Tel: +353 (0) 1 475 1444 |
|
Iarla Mongey, Public Relations Advisor to Uniphar Group |
|
About Uniphar plc
Headquartered in Dublin, Ireland, the Uniphar Group is an international diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions – Uniphar Pharma, Uniphar Medtech and Uniphar Supply Chain & Retail. The Group is active in Europe, North America, APAC and MENA and delivers to 160+ countries.
The Company's vision is to improve patient access to pharmaco-medical products and treatments by enhancing connectivity between manufacturers and healthcare stakeholders. Uniphar represents a strong combination of scale, growth, and profitability.
Uniphar Supply Chain & Retail
Uniphar Supply Chain & Retail is the leading pharmaceutical wholesaler in Ireland with a growing symbol group offering of retail pharmacies. The Group’s strategy for Uniphar Supply Chain & Retail is to grow our wholesale market share, our symbol group network and our own brand, in-licenced and consumer products portfolio.
Uniphar Medtech
Uniphar Medtech is a leading Pan-European medical device distributor and solutions partner. The Group’s strategy for Uniphar Medtech is to grow our service offering across Europe and expand our addressable market by serving new specialities and new manufacturers.
Uniphar Pharma
Uniphar Pharma operates a global business with high value services across the lifecycle of a pharmaceutical product. We enable pharma and biotech companies to bring innovative medicines to global markets and provide healthcare professionals with access to medicines they can’t source through traditional channels. Our strategy is to build a leading platform to provide the specialist support and expertise needed to improve access to these medicines.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE